In this blog, 3L staffer Colton Adams writes about Hemp’s future in the Bluegrass.
In this blog, 3L staffer Jordan Guancione explores how Kentucky divorce courts should value unborn racehorses by looking to how courts have divided unvested pensions and stock options. She examines the “immediate offset” method as a potential solution for dividing an asset whose future value remains uncertain.
Agriculture
In this blog, 2L staffer Kristen Bailey analyzes Disney's “Living with the Land” attraction that takes guests through a tour of one of Disney's greenhouses, showcasing their innovative and sustainable agricultural practices. Disney goes above state regulations and follows stricter self-created guidelines, posing the question of whether state law adequately protects indoor agriculture when Disney is going beyond state and federal regulations to create their own. This blog argues that states should enact more specific and detailed regulations regarding indoor agricultural practices in order to best protect our environment.
Agriculture
In this blog, 3L staffer Lakyn LeMaster analyzes how the increasing popularity of GLP-1 medications may be reshaping consumer food habits and, in turn, impacting Kentucky’s agricultural industry. LeMaster addresses the risks that changing demands could create for Kentucky, particularly as consumers purchase less ultra-processed and fast food while showing increased interest in fresh foods. Ultimately, she argues that Kentucky’s agricultural community should proactively monitor these trends and encourage diversification to ensure producers are prepared for an evolving market.
In this blog, 2L staffer Grace Hager analyzes the escalating legal crisis facing the "Clean Beauty" industry driven by 2026 FDA findings and new state-level bans. Hager explores the debate between the industry’s current reliance on self-defined clean standards versus the growing legal demand for lab-verified transparency. Ultimately, she takes the position that retailers must assume a heightened legal risk that can no longer be hidden by vague marketing claims.
In this blog, senior staffer Amy Rice argues that the FDA should fully embrace a "method-neutral" approach by accepting New Approach Methodologies (“NAMs”) as primary evidence of drug efficacy. She contends that traditional animal testing is often an outdated and poor predictor of human outcomes, whereas modern tools like organ-on-chip models offer superior scientific precision. Ultimately, Rice asserts that regulators must move beyond historical biases to implement the FDA Modernization Acts, thereby accelerating innovation and reducing the costs of biomedical and agricultural development.
